# Chiara Cremolini

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/chiara-cremolini/

## Facts

| Field | Value |
| --- | --- |
| Citations | 21,459 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 67 |
| i10-index | 249 |
| Last Known Institution | University of Pisa |
| OpenAlex ID | https://openalex.org/A5081985776 |
| ORCID iD | https://orcid.org/0000-0002-0520-4841 |
| Works | 987 |

## Researcher papers

- [FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study](https://scholariq.org/papers/folfoxiri-plus-bevacizumab-versus-folfiri-plus-bevacizumab-as-first-line/)
- [Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer](https://scholariq.org/papers/initial-therapy-with-folfoxiri-and-bevacizumab-for-metastatic-colorectal-cancer/)
- [Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer](https://scholariq.org/papers/trifluridine-tipiracil-and-bevacizumab-in-refractory-metastatic-colorectal/)
- [Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan](https://scholariq.org/papers/rechallenge-for-patients-with-i-ras-i-and-i-braf-i-wild-type-metastatic/)
- [PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer](https://scholariq.org/papers/pten-expression-and-kras-mutations-on-primary-tumors-and-metastases-in-the/)
- [Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study](https://scholariq.org/papers/fruquintinib-versus-placebo-in-patients-with-refractory-metastatic-colorectal/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Genetic factors in colorectal cancer](https://scholariq.org/topics/genetic-factors-in-colorectal-cancer/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)

## Researcher university

- [University of Pisa](https://scholariq.org/institutions/university-of-pisa/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.